Shopping Cart
- Remove All
- Your shopping cart is currently empty
FSC231 is a PSD-95/DLG/ZO-1 (PDZ) domain inhibitor of PICK1 with analgesic effects [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | FSC231 is a PSD-95/DLG/ZO-1 (PDZ) domain inhibitor of PICK1 with analgesic effects [1]. |
In vitro | FSC231 (50 μM) inhibits the interaction between GluR2 and PICK1 in COS7 cells [2]. |
In vivo | FSC231 (total 78.40 μg/kg daily, administered via intraperitoneal injection seven times, completed 3 hours before paclitaxel treatment) alleviates paclitaxel-induced neuralgia in rats [1]. Additionally, FSC231 (39.2 μg/kg/day, intraperitoneally, for 4 weeks) inhibits the development of diabetic cardiomyopathy in rats by partially suppressing ROS production and apoptosis through the PICK1/eNOS/cGMP pathway [3]. Animal Model: Paclitaxel-induced neuralgia in rats [1] Dosage: 78.40 μg/kg total Administration: i.p., daily, seven times, 3 hours prior to Paclitaxel Result: Mitigated changes in inflammatory cytokines (IL-6, TNF-α, and IL-10) and inhibited the phosphorylation of GSK-3β and ERK1/2. |
Molecular Weight | 313.14 |
Formula | C13H10Cl2N2O3 |
Cas No. | 1215849-96-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.